---
title: Dual-receptor T cell platform with Ab-TCR and costimulatory receptor achieves
  specificity and potency against AML
date: '2023-12-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38048594/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231205170723&v=2.17.9.post6+86293ac
source: Blood
description: Chimeric antigen receptor T cell (CAR T) therapy has produced remarkable
  clinical responses in B cell neoplasms. However, many challenges limit this class
  of agents for the treatment of other cancer types, in particular the lack of tumor-selective
  antigens for solid tumors and other hematological malignancies, such as Acute Myeloid
  Leukemia (AML), that may be addressed without significant risk of severe toxicities
  while providing sufficient abundance for efficient tumor suppression. One ...
disable_comments: true
---
Chimeric antigen receptor T cell (CAR T) therapy has produced remarkable clinical responses in B cell neoplasms. However, many challenges limit this class of agents for the treatment of other cancer types, in particular the lack of tumor-selective antigens for solid tumors and other hematological malignancies, such as Acute Myeloid Leukemia (AML), that may be addressed without significant risk of severe toxicities while providing sufficient abundance for efficient tumor suppression. One ...